{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:04:12Z","timestamp":1794243852238,"version":"4.9.0"},"reference-count":216,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.exphem.2025.104762","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T20:47:19Z","timestamp":1742676439000},"page":"104762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Harnessing the potential of gene-editing technology to overcome the current bottlenecks of CAR-T cell therapy in T-cell malignancies"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4793-210X","authenticated-orcid":false,"given":"Ahmed H.","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8646-5645","authenticated-orcid":false,"given":"Mohsen A.","family":"Khormi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0710-6048","authenticated-orcid":false,"given":"Wedad","family":"Mawkili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9176-0525","authenticated-orcid":false,"given":"Amirah","family":"Albaqami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2213-3758","authenticated-orcid":false,"given":"Sultan","family":"Areshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Aborasain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysa M.","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-602X","authenticated-orcid":false,"given":"Ali H.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4267-8787","authenticated-orcid":false,"given":"Mabrouk A.","family":"Abo-Zaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2025.104762_bib0001","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/cancers15010094","article-title":"Adoptive cell therapy for T-cell malignancies","volume":"15","author":"Fang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.exphem.2025.104762_bib0002","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bjh.18940","article-title":"A comparison of the International Consensus and 5th WHO classifications of T-cell lymphomas and histiocytic\/dendritic cell tumours","volume":"203","author":"Falini","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2025.104762_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100029","article-title":"T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions","volume":"1","author":"Kroeze","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.exphem.2025.104762_bib0004","series-title":"Peripheral T-Cell Lymphoma","author":"Rangoonwala","year":"2025"},{"key":"10.1016\/j.exphem.2025.104762_bib0005","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s11912-023-01464-8","article-title":"What is new in cutaneous T cell lymphoma?","volume":"25","author":"Morgenroth","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.exphem.2025.104762_bib0006","first-page":"2299","article-title":"HTLV-1 persistence and the oncogenesis of adult T-cell leukemia\/lymphoma","volume":"141","author":"Bangham","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0007","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.3390\/cancers14163955","article-title":"Novel targeted therapies for T-cell malignancies","volume":"14","author":"Tesio","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2025.104762_bib0008","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s12015-024-10786-4","article-title":"Beyond conventional treatments: exploring CAR-T cell therapy for cancer stem cell eradication","volume":"20","author":"Rabie","year":"2024","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.exphem.2025.104762_bib0009","unstructured":"U.S. Food and Drug Administration (FDA). AUCATZYL (abatacept). https:\/\/www.fda.gov\/vaccines-blood-biologics\/aucatzyl. Accessed June 15, 2024."},{"key":"10.1016\/j.exphem.2025.104762_bib0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0012","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0013","unstructured":"U.S. Food and Drug Administration. FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. FDA. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic. Accessed June 17, 2024."},{"key":"10.1016\/j.exphem.2025.104762_bib0014","unstructured":"U.S. Food and Drug Administration. FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma. FDA. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma. Accessed June 17, 2024."},{"key":"10.1016\/j.exphem.2025.104762_bib0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0016","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.exphem.2025.104762_bib0017","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2025.104762_bib0018","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/vaccines11010165","article-title":"CAR T-cell immunotherapy treating T-ALL: challenges and opportunities","volume":"11","author":"Ren","year":"2023","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.exphem.2025.104762_bib0019","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0020","article-title":"CAR T-cells for T-cell acute lymphoblastic leukemia","volume":"3","author":"Dourthe","year":"2024","journal-title":"EJC Paediatr Oncol"},{"key":"10.1016\/j.exphem.2025.104762_bib0021","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","article-title":"Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2025.104762_bib0022","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104762_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115888","article-title":"The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: an overview of clinical trials","volume":"169","author":"Moradi","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.exphem.2025.104762_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1388475","article-title":"Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review","volume":"14","author":"Moradi","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2025.104762_bib0025","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-edited CAR T cells for combinational therapy against T cell malignancies","volume":"35","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104762_bib0026","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/s41375-023-02039-z","article-title":"An \u201coff-the-shelf\u201d CD2 universal CAR-T therapy for T-cell malignancies","volume":"37","author":"Xiang","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104762_bib0027","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99442","article-title":"TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy","volume":"3","author":"Rasaiyaah","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.exphem.2025.104762_bib0028","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104762_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1407898","article-title":"Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines","volume":"7","author":"Raikar","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.exphem.2025.104762_bib0030","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104762_bib0031","unstructured":"Campana DMHW, inventor. Blockade of CD8 expression and chimeric antigen receptors for immunotherapy of T-cell and NK-cell malignancies; 2024. (Patent no. WO2024151213A3)."},{"key":"10.1016\/j.exphem.2025.104762_bib0032","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit?","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2025.104762_bib0033","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2023-181282","article-title":"Fratricide-resistant anti-CD2 chimeric antigen receptor T-cells with endogenous CD2 knockout are highly effective against T-cell neoplasms","volume":"142","author":"Angelos","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0034","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2025.104762_bib0035","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0036","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: potential causes and solutions","volume":"20","author":"Kouro","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.765097","article-title":"Optimizing the clinical impact of CAR-T cell therapy in B-cell acute lymphoblastic leukemia: looking back while moving forward","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0038","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0039","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2025.104762_bib0040","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0041","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0042","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood-2002-04-1130","article-title":"Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0043","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/sj.leu.2402636","article-title":"Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL","volume":"16","author":"van der Velden","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104762_bib0044","doi-asserted-by":"crossref","first-page":"116","DOI":"10.32607\/20758251-2015-7-3-116-125","article-title":"Clonal rearrangements and malignant clones in peripheral T-cell lymphoma","volume":"7","author":"Sidorova","year":"2015","journal-title":"Acta Naturae"},{"key":"10.1016\/j.exphem.2025.104762_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1491282","article-title":"Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects","volume":"12","author":"Alidadi","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.exphem.2025.104762_bib0046","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0047","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104762_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122683","article-title":"The paths toward non-viral CAR-T cell manufacturing: a comprehensive review of state-of-the-art methods","volume":"348","author":"Metanat","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.exphem.2025.104762_bib0049","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cancers12020287","article-title":"Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers","volume":"12","author":"Do","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.exphem.2025.104762_bib0050","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/cancers11050674","article-title":"CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.exphem.2025.104762_bib0051","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/labinvest.2017.25","article-title":"T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy","volume":"97","author":"Sackstein","year":"2017","journal-title":"Lab Invest"},{"key":"10.1016\/j.exphem.2025.104762_bib0052","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2025.104762_bib0053","doi-asserted-by":"crossref","first-page":"iqad006","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of T-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxf Open Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0054","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.exphem.2025.104762_bib0055","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-023-01894-9","article-title":"Outsmarting trogocytosis to boost CAR NK\/T cell therapy","volume":"22","author":"Ramezani","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.exphem.2025.104762_bib0056","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s41232-024-00358-x","article-title":"Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy","volume":"44","author":"Zhang","year":"2024","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.exphem.2025.104762_bib0057","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12943-024-02175-9","article-title":"Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells","volume":"23","author":"Yang","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.exphem.2025.104762_bib0058","first-page":"eabq3016","article-title":"Metabolic challenges and interventions in CAR","volume":"8","author":"Peng","year":"2023","journal-title":"T cell therapy. Sci Immunol."},{"key":"10.1016\/j.exphem.2025.104762_bib0059","article-title":"Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684642","article-title":"Engineered cytokine signaling to improve CAR T cell effector function","volume":"12","author":"Bell","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0061","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.7150\/thno.76854","article-title":"Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.exphem.2025.104762_bib0062","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/mt.2009.179","article-title":"Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors","volume":"17","author":"Modlich","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2025.104762_bib0063","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.exphem.2025.104762_bib0064","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1038\/s41467-024-47866-5","article-title":"A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID","volume":"15","author":"Cesana","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2025.104762_bib0065","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104762_bib0066","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.104762_bib0067","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0068","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867013","article-title":"The past, present, and future of non-viral CAR T cells","volume":"13","author":"Moretti","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0070","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"issue":"Suppl 3","key":"10.1016\/j.exphem.2025.104762_bib0071","first-page":"21","article-title":"CAR T-cell therapy: adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.exphem.2025.104762_bib0072","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.exphem.2025.104762_bib0073","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0074","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (Eds). The EBMT\/EHA CAR-T Cell Handbook. Cham, Switzerland: Springer; 2022.","DOI":"10.1007\/978-3-030-94353-0"},{"key":"10.1016\/j.exphem.2025.104762_bib0075","doi-asserted-by":"crossref","first-page":"e1576","DOI":"10.1002\/wsbm.1576","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"WIREs Mech Dis"},{"key":"10.1016\/j.exphem.2025.104762_bib0076","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2025.104762_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.exphem.2025.104762_bib0078","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.coviro.2015.03.011","article-title":"The history and market impact of CRISPR RNA-guided nucleases","volume":"12","author":"van Erp","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.exphem.2025.104762_bib0079","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.exphem.2025.104762_bib0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/bit.28260","article-title":"Genome editing technologies, mechanisms and improved production of therapeutic phytochemicals: opportunities and prospects","volume":"120","author":"Mitra","year":"2023","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.exphem.2025.104762_bib0081","doi-asserted-by":"crossref","DOI":"10.1038\/srep23549","article-title":"Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing","volume":"6","author":"Miyaoka","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2025.104762_bib0082","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40364-023-00509-1","article-title":"Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies","volume":"11","author":"Dabiri","year":"2023","journal-title":"Biomark Res"},{"key":"10.1016\/j.exphem.2025.104762_bib0083","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fgene.2018.00691","article-title":"Methodologies for improving HDR efficiency","volume":"9","author":"Liu","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.exphem.2025.104762_bib0084","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2025.104762_bib0085","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.stem.2022.09.001","article-title":"Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells","volume":"29","author":"Ferrari","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2025.104762_bib0086","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41587-024-02171-w","article-title":"Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors","volume":"43","author":"Suchy","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2025.104762_bib0087","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.exphem.2025.104762_bib0088","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1038\/s41467-021-26518-y","article-title":"Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo","volume":"12","author":"Ibraheim","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2025.104762_bib0089","doi-asserted-by":"crossref","first-page":"9145","DOI":"10.3390\/ijms25179145","article-title":"Electroporation delivery of Cas9 sgRNA ribonucleoprotein-mediated genome editing in sheep IVF zygotes","volume":"25","author":"Pi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2025.104762_bib0090","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/pharmaceutics16091197","article-title":"Advances in nanoparticles as non-viral vectors for efficient delivery of CRISPR\/Cas9","volume":"16","author":"Kim","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.exphem.2025.104762_bib0091","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41587-023-01888-4","article-title":"High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition","volume":"42","author":"Selvaraj","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2025.104762_bib0092","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91288.3","article-title":"Near-perfect precise on-target editing of human hematopoietic stem and progenitor cells","volume":"12","author":"Cloarec-Ung","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.exphem.2025.104762_bib0093","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1038\/s41467-023-40344-4","article-title":"Simultaneous inhibition of DNA-PK and Pol\u03f4 improves integration efficiency and precision of genome editing","volume":"14","author":"Wimberger","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.exphem.2025.104762_bib0094","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10142-025-01560-x","article-title":"AZD7648 (DNA-PKcs inhibitor): a two-edged sword for editing genomes","volume":"25","author":"Sajjad","year":"2025","journal-title":"Funct Integr Genomics"},{"key":"10.1016\/j.exphem.2025.104762_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.exphem.2025.104762_bib0096","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1097\/HS9.0000000000000671","article-title":"The EHA research roadmap: hematopoietic stem cell gene therapy","volume":"6","author":"Naldini","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.exphem.2025.104762_bib0097","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910355","article-title":"Comparison of the feasibility, efficiency, and safety of genome editing technologies","volume":"22","author":"Gonz\u00e1lez Castro","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2025.104762_bib0098","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/15476286.2019.1582974","article-title":"CRISPR-Cas in Streptococcus pyogenes","volume":"16","author":"Le Rhun","year":"2019","journal-title":"RNA Biol"},{"key":"10.1016\/j.exphem.2025.104762_bib0099","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1021\/acsomega.2c05583","article-title":"Insights into the mechanism of CRISPR\/Cas9-based genome editing from molecular dynamics simulations","volume":"8","author":"Bhattacharya","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.exphem.2025.104762_bib0100","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2025.104762_bib0101","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","article-title":"CRISPR-Cas9 knockin mice for genome editing and cancer modeling","volume":"159","author":"Platt","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2025.104762_bib0102","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13059-015-0846-3","article-title":"Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency","volume":"16","author":"Dang","year":"2015","journal-title":"Genome Biol"},{"key":"10.1016\/j.exphem.2025.104762_bib0103","first-page":"353","article-title":"Mechanism and applications of CRISPR\/Cas-9-mediated genome editing","volume":"15","author":"Asmamaw","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.exphem.2025.104762_bib0104","doi-asserted-by":"crossref","first-page":"bpy002","DOI":"10.1093\/biomethods\/bpy002","article-title":"Applications of the CRISPR\/Cas system beyond gene editing","volume":"3","author":"Anton","year":"2018","journal-title":"Biol Methods Protoc"},{"key":"10.1016\/j.exphem.2025.104762_bib0105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cell.2016.09.006","article-title":"Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing","volume":"167","author":"Amabile","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2025.104762_bib0106","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/blood-2016-01-678136","article-title":"Ethical and regulatory aspects of genome editing","volume":"127","author":"Kohn","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2022.146518","article-title":"Overview of advances in CRISPR\/deadCas9 technology and its applications in human diseases","volume":"830","author":"Kanafi","year":"2022","journal-title":"Gene"},{"key":"10.1016\/j.exphem.2025.104762_bib0108","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.1038\/s41467-024-52483-3","article-title":"Evolved cytidine and adenine base editors with high precision and minimized off-target activity by a continuous directed evolution system in mammalian cells","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2025.104762_bib0109","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.exphem.2025.104762_bib0110","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.104762_bib0111","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41551-023-01026-0","article-title":"Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice","volume":"7","author":"Everette","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.exphem.2025.104762_bib0112","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41587-022-01445-5","article-title":"Verve takes base editors into humans","volume":"40","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2025.104762_bib0113","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2025.104762_bib0114","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2024-203546","volume":"144","author":"Diorio","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0115","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","article-title":"Genotoxic effects of base and prime editing in human hematopoietic stem cells","volume":"42","author":"Fiumara","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2025.104762_bib0116","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.exphem.2025.104762_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117516","article-title":"Optimizing CRISPR\/Cas9 precision: mitigating off-target effects for safe integration with photodynamic and stem cell therapies in cancer treatment","volume":"180","author":"Merlin","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.exphem.2025.104762_bib0118","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1016\/j.molcel.2021.07.035","article-title":"Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells","volume":"81","author":"Donohoue","year":"2021","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2025.104762_bib0119","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.omtn.2022.06.003","article-title":"Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells","volume":"29","author":"Madison","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.exphem.2025.104762_bib0120","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2023114188","article-title":"Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of CD4+ T-cells for the treatment of Hyper IgM1","volume":"42","author":"Canarutto","year":"2023","journal-title":"Embo J"},{"key":"10.1016\/j.exphem.2025.104762_bib0121","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12967-024-04917-1","article-title":"Unraveling metagenomics through long-read sequencing: a comprehensive review","volume":"22","author":"Kim","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0122","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41587-019-0217-9","article-title":"Accurate circular consensus long-read sequencing improves variant detection and assembly of a human genome","volume":"37","author":"Wenger","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2025.104762_bib0123","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41592-022-01730-w","article-title":"Method of the year: long-read sequencing","volume":"20","author":"Marx","year":"2023","journal-title":"Nat Methods"},{"key":"10.1016\/j.exphem.2025.104762_bib0124","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3324\/haematol.2023.283848","article-title":"Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia","volume":"109","author":"Oh","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2025.104762_bib0125","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0126","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0127","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104762_bib0128","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s41375-023-01948-3","article-title":"Inserting EF1\u03b1-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection","volume":"37","author":"Jiang","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104762_bib0129","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1089\/hum.2023.029","article-title":"Universal anti-CD7 CAR-T cells targeting T-ALL and functional analysis of CD7 antigen on T\/CAR-T cells","volume":"34","author":"Xie","year":"2023","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.exphem.2025.104762_bib0130","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0131","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2025.104762_bib0132","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1182\/blood-2022-165733","article-title":"A novel universal CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.exphem.2025.104762_bib0133","article-title":"P356: phase 1\/2 dose-escalation study of anti-CD7 allogenic CAR-T cell in relapsed or refractory(R\/R) T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma(T-ALL\/LBL)","volume":"7","author":"Ghobadi","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.exphem.2025.104762_bib0134","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2025.104762_bib0135","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/s41375-023-02018-4","article-title":"CD7 targeted \u201coff-the-shelf\u201d CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies","volume":"37","author":"Li","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104762_bib0136","doi-asserted-by":"crossref","DOI":"10.4161\/onci.22841","article-title":"T-cell modulatory properties of CD5 and its role in antitumor immune responses","volume":"2","author":"Tabbekh","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.exphem.2025.104762_bib0137","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","article-title":"Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia","volume":"77","author":"Campana","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0138","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.12042","article-title":"The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report","volume":"159","author":"Patel","year":"2012","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2025.104762_bib0139","article-title":"T-cells resist CD5 CAR mediated fratricide by continuously degrading CD5 protein","volume":"208","author":"Ma","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0140","article-title":"Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity","volume":"5","author":"Ma","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0141","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2025.104762_bib0142","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2022-166605","article-title":"Clinical development of Senza5TM CART5: a novel dual population CD5 CRISPR-Cas9 knocked out anti-CD5 chimeric antigen receptor T cell product for relapsed and refractory CD5+ nodal T-cell lymphomas","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2025.104762_bib0143","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-136860","article-title":"CRISPR-Cas9 knock out of CD5 enhances the anti-tumor activity of chimeric antigen receptor T cells","volume":"136","author":"Chun","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0144","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","article-title":"The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains","volume":"29","author":"Dai","year":"2021","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2025.104762_bib0145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-139605","article-title":"CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through novel CAR engineering","volume":"136","author":"Majzner","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0146","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1182\/bloodadvances.2022007891","article-title":"CD58 loss in tumor cells confers functional impairment of CAR T cells","volume":"6","author":"Yan","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104762_bib0147","doi-asserted-by":"crossref","first-page":"eaag1209","DOI":"10.1126\/scitranslmed.aag1209","article-title":"TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance","volume":"9","author":"Yang","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0148","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0149","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.exphem.2025.104762_bib0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780145","article-title":"Strategies to circumvent the side-effects of immunotherapy using allogeneic CAR-T cells and boost its efficacy: results of recent clinical trials","volume":"12","author":"Smirnov","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0151","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.17544","article-title":"Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells","volume":"195","author":"Sanber","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2025.104762_bib0152","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.exphem.2025.104762_bib0153","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","article-title":"HLA-haploidentical stem cell transplantation after removal of \u03b1\u03b2+ T and B cells in children with nonmalignant disorders","volume":"124","author":"Bertaina","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0154","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jaci.2017.07.008","article-title":"T-cell receptor \u03b1\u03b2+ and CD19+ cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency","volume":"141","author":"Shah","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0155","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fbioe.2020.00678","article-title":"Straightforward generation of ultrapure off-the-shelf allogeneic CAR-T cells","volume":"8","author":"Juillerat","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.exphem.2025.104762_bib0156","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jcyt.2013.05.014","article-title":"Depletion of T-cell receptor alpha\/beta and CD19 positive cells from apheresis products with the CliniMACS device","volume":"15","author":"Schumm","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.exphem.2025.104762_bib0157","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640082","article-title":"Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma","volume":"12","author":"Mart\u00ednez Bedoya","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0158","first-page":"183","article-title":"Humanized chimeric antigen receptor (CAR) T cells","volume":"3","author":"Kozani","year":"2021","journal-title":"J Cancer Immunol (Wilmington)"},{"key":"10.1016\/j.exphem.2025.104762_bib0159","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic CAR-T cells in hematological malignancies","volume":"24","author":"Mansoori","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.exphem.2025.104762_bib0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-023-03586-1","article-title":"Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.exphem.2025.104762_bib0161","article-title":"Genome editing approaches for universal chimeric antigen receptor T cells","volume":"3","author":"Mishra","year":"2024","journal-title":"EJC Paediatr Oncol"},{"key":"10.1016\/j.exphem.2025.104762_bib0162","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.exphem.2025.104762_bib0163","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.omtm.2022.05.010","article-title":"Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application","volume":"26","author":"Kitano","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.exphem.2025.104762_bib0164","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2025.104762_bib0165","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2025.104762_bib0166","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005857","article-title":"CD47 expression is critical for CAR T-cell survival in vivo","volume":"11","author":"Beckett","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.exphem.2025.104762_bib0167","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.stem.2013.11.014","article-title":"An effective approach to prevent immune rejection of human ESC-derived allografts","volume":"14","author":"Rong","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2025.104762_bib0168","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","article-title":"Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells","volume":"5","author":"Wang","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.exphem.2025.104762_bib0169","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","article-title":"Engineered off-the-shelf therapeutic T cells resist host immune rejection","volume":"39","author":"Mo","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2025.104762_bib0170","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2021.39.15_suppl.2527","article-title":"Safety and PK\/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)\/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy","volume":"39","author":"Tees","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2025.104762_bib0171","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/mt.2015.104","article-title":"A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy","volume":"23","author":"Valton","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2025.104762_bib0172","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2025.104762_bib0173","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1063454","article-title":"Analysis of causes for poor persistence of CAR-T cell therapy in vivo","volume":"14","author":"Kong","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0174","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109625","article-title":"PD-1 disrupted CAR-T cells in the treatment of solid tumors: promises and challenges","volume":"121","author":"McGowan","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.exphem.2025.104762_bib0175","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","article-title":"CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells","volume":"11","author":"Zhang","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0176","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1315283","article-title":"TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells","volume":"15","author":"Cianciotti","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0177","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2025.104762_bib0178","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.3390\/ijms23063207","article-title":"Simultaneous genetic ablation of PD-1, LAG-3, and TIM-3 in CD8 T cells delays tumor growth and improves survival outcome","volume":"23","author":"Ciraolo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2025.104762_bib0179","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-21-0694","article-title":"PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity","volume":"12","author":"Wiede","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2025.104762_bib0180","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12967-021-03146-0","article-title":"CRISPR\/Cas9-mediated TGF\u03b2RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro","volume":"19","author":"Alishah","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0181","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2025.104762_bib0182","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001688","article-title":"Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function","volume":"9","author":"Kumar","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.exphem.2025.104762_bib0183","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1158\/0008-5472.CAN-18-0030","article-title":"CRISPR\/Cas9-mediated knockout of DGK improves antitumor activities of human T cells","volume":"78","author":"Jung","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2025.104762_bib0184","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0185","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood.2021012714","article-title":"Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy","volume":"139","author":"Yoshikawa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0186","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2025.104762_bib0187","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41586-023-06546-y","article-title":"Reductive carboxylation epigenetically instructs T cell differentiation","volume":"621","author":"Jaccard","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.104762_bib0188","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-22-1319","article-title":"Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T-cell function","volume":"14","author":"Jain","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2025.104762_bib0189","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.omto.2022.12.003","article-title":"Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels","volume":"28","author":"Lv","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.exphem.2025.104762_bib0190","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.104762_bib0191","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","article-title":"Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy","volume":"576","author":"Wei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.104762_bib0192","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3390\/cancers12061704","article-title":"CRISPR-mediated non-viral site-specific gene integration and expression in T cells: protocol and application for T-cell therapy","volume":"12","author":"Od\u00e9","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2025.104762_bib0193","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1038\/s41375-021-01217-1","article-title":"Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia","volume":"35","author":"Rivas","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104762_bib0194","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.immuni.2021.11.004","article-title":"Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity","volume":"54","author":"Hanna","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2025.104762_bib0195","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2025.104762_bib0196","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood-2024-206439","article-title":"IL-10 expressing CD19 CAR-T cells induce complete remission and improve long-term protection in relapsed or refractory B-cell hematological malignancies","volume":"144","author":"Guo","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0197","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/cancers13040872","article-title":"RNA-seq analysis reveals CCR5 as a key target for CRISPR gene editing to regulate in vivo NK cell trafficking","volume":"13","author":"Levy","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2025.104762_bib0198","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953849","article-title":"Overcoming tumor resistance mechanisms in CAR-NK cell therapy","volume":"13","author":"Valeri","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0199","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jcyt.2022.02.006","article-title":"CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma","volume":"24","author":"Schomer","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.exphem.2025.104762_bib0200","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0201","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood-2018-99-111766","article-title":"GM-CSF blockade during chimeric antigen receptor T cell therapy reduces cytokine release syndrome and neurotoxicity and may enhance their effector functions","volume":"132","author":"Sterner","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0202","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","article-title":"Granulocyte\u2013macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators","volume":"294","author":"Sachdeva","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2025.104762_bib0203","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41375-022-01572-7","article-title":"GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity","volume":"36","author":"Cox","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104762_bib0204","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41421-021-00255-4","article-title":"CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy","volume":"7","author":"Yi","year":"2021","journal-title":"Cell Discov"},{"key":"10.1016\/j.exphem.2025.104762_bib0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-020-00166-2","article-title":"Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes","volume":"9","author":"Kang","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.exphem.2025.104762_bib0206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.2016005","article-title":"IL-6\/IFN-\u03b3 double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro","volume":"18","author":"Zhang","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.exphem.2025.104762_bib0207","article-title":"Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells","volume":"5","author":"Yoshikawa","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0208","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2025.104762_bib0209","article-title":"Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation","volume":"14","author":"Netsrithong","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2025.104762_bib0210","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/10430340460732463","article-title":"Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease","volume":"15","author":"Serafini","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.exphem.2025.104762_bib0211","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2025.104762_bib0212","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2024-200809","article-title":"Phase 1 dose-escalation and dose-expansion study to evaluate the safety and tolerability of anti-CD7 allogeneic CAR T-cells (WU-CART-007) in patients with CD7+ T-cell non-Hodgkin lymphoma","volume":"144","author":"Kramer","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104762_bib0213","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2025.104762_bib0214","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2025.104762_bib0215","doi-asserted-by":"crossref","first-page":"TPS2676","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2676","article-title":"A phase 1\/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9\u2013engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors","volume":"42","author":"Pal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2025.104762_bib0216","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","article-title":"Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial","volume":"31","author":"Pan","year":"2025","journal-title":"Nat Med"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25000530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25000530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T13:13:44Z","timestamp":1749647624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X25000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":216,"alternative-id":["S0301472X25000530"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2025.104762","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing the potential of gene-editing technology to overcome the current bottlenecks of CAR-T cell therapy in T-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2025.104762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104762"}}